Abstract
The regulatory and research landscape for therapeutics is continually evolving globally. These changes are influenced by factors such as requirements by the regulatory agencies and health authorities, or strategic positioning of the product in the marketplace. Challenges also arise from the necessity to develop a therapeutic product in conjunction with an assay. The therapeutic company finds itself in unfamiliar territory and might not fully appreciate unforeseen challenges that could delay and even potentially derail a development program. Choosing the right partner to develop the assay and strategic choices regarding the source of regulatory expertise can be the difference between failure and success. This article provides considerations for regulatory professionals working within pharmaceutical or biotech companies that are actively pursuing In Vitro or companion diagnostics to accompany the products in their therapeutic portfolio.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
